头孢他啶-阿维巴坦与头孢洛扎-他唑巴坦治疗美国多重耐药铜绿假单胞菌感染的有效性比较(CACTUS):一项多中心、回顾性、观察性研究
这项在美国28家医院开展的多中心回顾性观察性研究,纳入2016年1月1日至2023年12月31日期间420例成人多重耐药铜绿假单胞菌肺炎或菌血症患者,按1:1匹配后比较头孢洛扎-他唑巴坦与头孢他啶-阿维巴坦的疗效。结果显示头孢洛扎-他唑巴坦组第30天临床成功率61%,头孢他啶-阿维巴坦组52%,调整后比值比2.07(95%CI 1.16-3.70);肺炎亚组差异更明显,菌血症亚组无显著差异;两组全因死亡率无显著差异,治疗中出现耐药均常见。
要点
- 头孢洛扎-他唑巴坦组临床成功61%(128/210),头孢他啶-阿维巴坦组52%(109/210),aOR 2.07(95%CI 1.16-3.70)。
- 肺炎亚组临床成功头孢洛扎-他唑巴坦组63%(110/175) vs 头孢他啶-阿维巴坦组51%(89/175),aOR 2.34(95%CI 1.22-4.47)。
- 两组30天和90天全因死亡率无显著差异;治疗中出现耐药头孢洛扎-他唑巴坦组22%(38/173) vs 头孢他啶-阿维巴坦组23%(40/177)。
核心结论
- 对于多重耐药铜绿假单胞菌侵袭性感染,头孢洛扎-他唑巴坦治疗后的临床成功率高于头孢他啶-阿维巴坦。
- 差异主要由接受头孢洛扎-他唑巴坦治疗的肺炎患者应答率改善所驱动。
- 两组全因死亡率无显著差异,两种药物治疗中出现耐药均常见。
研究设计与样本
- 多中心、回顾性、观察性研究,在美国28家医院开展,时间为2016年1月1日至2023年12月31日。
- 纳入年龄≥18岁、微生物学确诊多重耐药铜绿假单胞菌肺炎或菌血症、接受头孢洛扎-他唑巴坦或头孢他啶-阿维巴坦治疗超过48小时的成人患者。
- 按研究中心、疾病严重程度、治疗启动时间(≤72小时或>72小时)和感染类型进行1:1匹配,共纳入420例,每组210例。
- 主要结局为第30天临床成功,定义为生存、感染体征和症状缓解且完成既定疗程、无铜绿假单胞菌复发感染。
- 次要结局包括全因死亡率和研究药物耐药性的产生。
主要发现
- 420例中350例(83%)为肺炎,70例(17%)为菌血症;治疗启动时336例(80%)在重症监护室,296例(70%)接受机械通气,168例(40%)需要血管升压药支持。
- 总体临床成功:头孢洛扎-他唑巴坦组61%(128/210) vs 头孢他啶-阿维巴坦组52%(109/210),条件logistic回归分析显示头孢洛扎-他唑巴坦相比头孢他啶-阿维巴坦的调整后比值比(aOR)为2.07(95%CI 1.16-3.70)。
- 肺炎患者临床成功:头孢洛扎-他唑巴坦组63%(110/175) vs 头孢他啶-阿维巴坦组51%(89/175),aOR 2.34(95%CI 1.22-4.47)。
- 菌血症患者临床成功率:头孢洛扎-他唑巴坦组51%(18/35) vs 头孢他啶-阿维巴坦组57%(20/35),OR 0.76(95%CI 0.23-2.57)。
- 基线分离株进行药敏试验的患者中,治疗中出现耐药:头孢洛扎-他唑巴坦组22%(38/173) vs 头孢他啶-阿维巴坦组23%(40/177);两组30天或90天死亡率无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce. Pharmacokinetic and pharmacodynamic differences between the agents might affect clinical response rates. We aimed to compare the effectiveness of ceftolozane-tazobactam and ceftazidime-avibactam for treatment of invasive multidrug-resistant P aeruginosa infections. METHODS: This multicentre, retrospective, observational study was conducted at 28 hospitals in the USA between Jan 1, 2016, and Dec 31, 2023. Eligible patients were adults (age ≥18 years old) with microbiologically confirmed multidrug-resistant P aeruginosa pneumonia or bacteraemia treated with ceftolozane-tazobactam or ceftazidime-avibactam for more than 48 h. Patients were matched (1:1) by study site, severity of illness, time to treatment initiation (≤72 h or >72 h), and infection type. The primary outcome was clinical success at day 30, which was defined as survival, resolution of signs and symptoms of infection with the intended treatment course, and the absence of recurrent infection due to P aeruginosa. Secondary outcomes included all-cause mortality and development of resistance to study drug. FINDINGS: 420 eligible patients were included (210 in each treatment group), of whom 350 (83%) had pneumonia and 70 (17%) had bacteraemia. Baseline demographics, comorbidities, and severity of illness indicators were similar between groups. On treatment initiation, 336 (80%) patients were in the intensive care unit, 296 (70%) were receiving mechanical ventilation, and 168 (40%) required vasopressor support. Clinical success was observed in 128 (61%) of 210 patients treated with ceftolozane-tazobactam and 109 (52%) of 210 patients treated with ceftazidime-avibactam. By conditional logistic regression analysis, the adjusted odds ratio (aOR) of success after treatment with ceftolozane-tazobactam compared with ceftazidime-avibactam was 2·07 (95% CI 1·16-3·70). For patients with pneumonia, clinical success was observed in 110 (63%) of 175 patients in the ceftolozane-tazobactam group and 89 (51%) of 175 patients in the ceftazidime-avibactam group (aOR 2·34 [95% CI 1·22-4·47]). Among patients with bacteraemia, rates of clinical success were 51% (18 of 35 patients) for patients treated with ceftolozane-tazobactam and 57% (20 of 35 patients) for those treated with ceftazidime-avibactam (0·76 [0·23-2·57]). There were no significant differences between groups in 30-day or 90-day mortality. Among patients whose baseline isolates were tested for susceptibility, resistance developed in 22% (38 of 173) of patients treated with ceftolozane-tazobactam and 23% (40 of 177) of patients treated with ceftazidime-avibactam. INTERPRETATION: Treatment with ceftolozane-tazobactam resulted in higher rates of clinical success compared with ceftazidime-avibactam for invasive infections due to multidrug-resistant P aeruginosa. Differences were driven by improved response rates for patients with pneumonia who were treated with ceftolozane-tazobactam. There were no significant differences between study groups with respect to all-cause mortality; treatment-emergent resistance was common with both agents. FUNDING: Merck Sharp & Dohme.
引用
- Shields RK, Abbo LM, Ackley R, et al. Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study. Lancet Infect Dis. 2024. PMID: 39701120. doi:10.1016/S1473-3099(24)00648-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。